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Atopic dermatitis (AD) is a multi-factorial skin disease
with a complex inflammatory signature including type
2 and type 17 activation. Although colonization by
S.aureus iscommon inAD, themechanismsrendering
an organismprone to dysbiosis, and the role of IL-17A
in the control of S. aureus-induced skin inflammation,
are not well understood. Here, we show several path-
ological aspects of AD, including type 2/type 17
immune responses, elevated IgE, barrier dysfunction,
pruritus, and importantly, spontaneous S. aureus
colonization in JunBDep mice, with a large transcrip-
tomic overlap with AD. Additionally, using Rag1/
mice, we demonstrate that adaptive immune cells
are necessary for protection against S. aureus coloni-
zation. Prophylactic antibiotics, but not antibiotics
after establisheddysbiosis, reduce IL-17A expression
and skin inflammation, examined using Il17a-eGFP
reporter mice. Mechanistically, keratinocytes lacking
JunB exhibit higher MyD88 levels in vitro and in vivo,
previously shown to regulate S. aureus colonization.
In conclusion, our data identify JunB as an upstream
regulator of microbiota-immune cell interactions and
characterize the IL-17A response upon spontaneous
dysbiosis.INTRODUCTION
Atopic dermatitis (AD) is a debilitating, chronic inflammatory skin
disease affecting 15%–20% of children and up to 10% of adults
(Weidinger et al., 2018). AD is characterized by epidermal hyper-
plasia, infiltration of innate and adaptive immune cells into the
dermis, severe pruritus, and S. aureus colonization and superin-844 Cell Reports 29, 844–859, October 22, 2019 ª 2019 The Authors
This is an open access article under the CC BY license (http://creativefections (Geoghegan et al., 2018; Weidinger et al., 2018). The
pathogenesis of AD is not well understood, although barrier de-
fects, microbial dysbiosis, genetic predisposition, and environ-
mental factors are thought to contribute to disease.
Transcriptomic analysis of AD patient biopsies has shown
enrichment for type 2 immune pathways, the importance of
which is highlighted by the efficacy of dupilumab, an IL-4Ra anti-
body that inhibits IL-4 and IL-13 signaling in AD patients (Simp-
son et al., 2016). However, higher levels of IL-17 and upregula-
tion of the IL-17 signaling pathway have also been observed in
AD (Koga et al., 2008;Werfel et al., 2016). Interestingly, transcrip-
tomic analysis comparing pediatric and adult AD skin biopsies
showedmore dominant Th17 pathway activation in pediatric pa-
tients, which accompanied higher levels of IL-36 expression
(Brunner et al., 2018). Whether the increase in IL-17 observed
in AD is protective or pathological remains to be determined. In
inflammatory bowel disease, IL-17A has been shown to be pro-
tective for the barrier (Uluçkan and Wagner, 2017), and animal
studies similarly suggest that IL-17A and its receptor maintain
the skin barrier function (Naik et al., 2015; Floudas et al., 2017).
In addition, IL-17A is postulated to lead to increased anti-micro-
bial production from epithelial cells, which is lower in AD
compared with psoriasis (Uluçkan and Wagner, 2017). Consis-
tent with this, recombinant IL-17A given at the time of
S. aureus challenge rescues the increased inflammation
observed in TCRgd T cell-deficient mice, suggesting a protective
role of IL-17A in S. aureus-induced skin inflammation (Cho et al.,
2010). Furthermore, IL-17A-secreting dendritic cells interacting
with the skin microbiota have been shown to be essential to pro-
tect the skin from S. aureus infections (Naik et al., 2015). These
studies suggest a protective role of IL-17A signaling in
S. aureus colonization, through effects of the commensal bacte-
ria. In contrast, mice lacking IL-17A/F have reduced skin inflam-
mation upon S. aureus challenge, implicating a complex role of
IL-17A during dysbiosis (Liu et al., 2017; Nakagawa et al.,
2017). Therefore, the role of IL-17 remains unclear in cutaneous










Figure 1. Spontaneous S. aureus Colonization with AD Features Is Observed in JunBDep Mice
(A) Representative images of H&E staining of skin from control and JunBDep mice at 6–7 months of age (n > 10 per genotype). The yellow scale bar indicates
200 mm.
(B) Representative images of Ym1 staining of skin from control and JunBDep mice at 6–7 months (n = 4, 4).
(C) TSLP levels in skin lysates of control and JunBDep mice at 2 (n = 3, 4) and 6–7 months (n = 11, 12).
(D) IL-33 levels in skin lysates of control and JunBDep mice at 2 (n = 3, 4) and 6–7 months (n = 11, 12).
(E) Serum IgE levels of control and JunBDep mice at 6–7 months of age (n = 4, 4).
(F) Scratch bouts of control and JunBDep mice at 6–7 months of age (n = 4, 4).
(G) Representative images of Gram staining of skin from control and JunBDepmice at 6–7months (n > 10 per genotype). Arrows indicate Gram-positive colonies of
bacteria. The yellow scale bar indicates 200 mm.
(legend continued on next page)
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understand how this cytokine interacts with type 2 inflammation,
barrier defects and the microbiota.
There is strong evidence to suggest that S. aureus exacer-
bates AD (Chen et al., 2018; Geoghegan et al., 2018).
S. aureus colonization is observed at a higher frequency in le-
sional skin, and bacterial load correlates with disease severity
(Gong et al., 2006). However, it remains unclear whether
S. aureus colonization is a cause or a consequence of AD pathol-
ogy. The heterogeneity of the skin microbiome, which influences
S. aureus colonization, varies depending on the body site and
further complicates investigations into the role of S. aureus in
AD (Kong et al., 2012). Thus, the question of whether dysbiosis
precedes S. aureus infection and type 2 immune activation or
is secondary to barrier perturbation, resulting in type 2 immune
activation, remains unresolved. A recent study showed that dys-
biosis can be detected before the onset of inflammatory lesions
in children, suggesting that S. aureus colonization might be
causal to AD (Meylan et al., 2017).
The molecular mechanisms leading to S. aureus colonization
and superinfections in AD patients remains poorly understood.
Two recent studies identified an important role for MyD88
signaling in S. aureus colonization in mice (Liu et al., 2017; Na-
kagawa et al., 2017). However, whereas Liu et al. (2017) sug-
gested that deletion of MyD88 in keratinocyte reduces disease
burden, Nakagawa et al. (2017) concluded that MyD88
signaling in T cells is sufficient to control S. aureus colonization
and skin inflammation. Both studies demonstrated IL-17A
production downstream of S. aureus and that IL-17A/F dou-
ble-knockout mice have reduced S. aureus colonization. These
effects are attributed to the secretion of IL-1 family members
from keratinocytes, particularly IL-36a. However, these studies
are limited by the challenge method of S. aureus administration,
which does not reflect the natural development of dysbiosis re-
ported in AD. Indeed, a major impediment to our understanding
of dysbiosis has been the paucity of mouse models with spon-
taneous S. aureus colonization. Mice lacking the membrane
protease ADAM-17 are prone to cutaneous dysbiosis and
AD-like skin inflammation, and Kobayashi et al. (2015) exploited
this observation to demonstrate that Corynebacterium bovis in-
duces type 2 inflammation, whereas S. aureus exacerbates dis-
ease. Nevertheless, several outstanding questions regarding
the role keratinocytes and T cells in dysbiosis-induced inflam-
mation and the regulation and cellular sources of IL-17A within
the skin remain unsolved.
Here we show that mice with epidermal deletion of
JunB/AP-1 exhibit spontaneous skin inflammation with
several hallmarks of AD, including high IgE, barrier dysfunc-
tion, type 2 inflammation, pruritus, and, critically, sponta-
neous S. aureus colonization. Using this mouse model of
cutaneous dysbiosis, we demonstrate a critical role for the
adaptive immune system in preventing superinfections and
investigate the effect of prophylactic and post-infection anti-
biotic treatment. Mechanistically, we explored the relationship(H) Representative images of S. aureus immunofluorescence staining of skin from
S. aureus colonies.
(I) Percentage of JunBDep mice positive for S. aureus colonization, as assessed b
(J) Outside-in barrier assay using toluidine blue dye at embryonic day 17.5 (n = 6
846 Cell Reports 29, 844–859, October 22, 2019between S. aureus colonization and IL-17A production within
the skin and report an important role for JunB in regulating
MyD88 expression within keratinocytes. Our data resolve
outstanding questions about the role of S. aureus in eczema-
tous inflammation and describe a model of spontaneous dys-
biosis with chronic inflammation.
RESULTS
Spontaneous S. aureus Colonization with AD-like
Features Is Observed in JunBDep Mice
We have previously shown that JunBDep mice, which have a
deletion of JunB in K5-expressing cells, exhibit spontaneous
chronic skin inflammation with concurrent bone loss through
IL-17 signaling (Uluçkan and Wagner, 2016; Meixner et al.,
2008; Pflegerl et al., 2009; Uluçkan et al., 2016; Singh et al.,
2018). Upon further characterization of the skin inflammation
of these mice, we observed spontaneous S. aureus coloniza-
tion, a hallmark of AD. As mouse models of AD with sponta-
neous dysbiosis and clinical translatability are currently lacking
(Jin et al., 2009; Ewald et al., 2017), we further investigated the
pathophysiological characteristics of skin inflammation in these
mice. JunBDep mice develop severe skin inflammation with
hyperkeratosis and immune cell infiltration by 6 months of
age (Figure 1A). We show that JunBDep skin has infiltration of
Ym1-positive cells (Figure 1B), increased TSLP and IL-33 levels
in skin (Figures 1C and 1D), elevated serum IgE (Pflegerl et al.,
2009) (Figure 1E), and significant pruritus (Figure 1F), all impor-
tant hallmarks of type 2 inflammation and AD (Welch et al.,
2002; Nair et al., 2003; Bird, 2005; Cevikbas and Steinhoff,
2012; Doherty et al., 2013; Wilson et al., 2013; Turner and
Zhou, 2014).
Additionally, Gram staining and immunofluorescence analysis
using a specific S. aureus antibody showed extensive coloniza-
tion by Gram-positive S. aureus on the skin surface of JunBDep
mice (Figures 1G and 1H). We confirmed the identity of the
Gram-positive bacteria to be S. aureus by growth and fermenta-
tion (yellow appearance) on mannitol-salt agar plates, a specific
ability of S. aureus (Figure S1A), and measured colony-forming
units (CFUs) of S. aureus (Figure S1B). We also isolated single
colonies and carried out PCR with S. aureus-specific primers,
as well as S. aureus-specific gyrase (gyr) (Figure S1C). At
6–7 months of age, 100% of JunBDep mice had S. aureus coloni-
zation and skin inflammation, whereas up to 3 months of age, no
S. aureus colonization was observed (Figure 1I). To determine
the kinetics of dysbiosis in these mice, we carried out Gram
staining, coupled with immunofluorescence for keratin 6 as a
marker of early inflammatory signals on keratinocytes at
2 days, 1month, and 3months post-birth.We observed sporadic
Gram-negative colonies with surrounding keratinocytes posi-
tively stained for keratin 6, suggesting that prior to the coloniza-
tion of S. aureus, someGram-negative bacteria might be present
in JunBDep skin (Figure S2).control and JunBDepmice at 6–7months (n > 10 per genotype). Arrow indicates
y IF for S. aureus.
, 6).
To determine the origin of S. aureus colonizing the skin of
JunBDep mice, we carried out PCR analysis for genes that are
human specific and rarely found in murine-adapted strains
(Holtfreter et al., 2013). These include the immune invasion
gene cluster including staphylokinase (sak) and staphylococcal
complement inhibitor (scn) and a human-specific prophase inte-
grase-gene, sa3int. In addition, we also analyzed the presence of
mecA, the gene responsible for methicillin resistance (Fig-
ure S1C). Most of the colonies isolated from JunBDep skin were
positive for sak, scn, and sa3int but were negative formecA, indi-
cating that these bacteria are most likely human adapted but not
methicillin resistant. These data suggest that dysbiosis allows
S. aureus, originating presumably from caretakers, to colonize
the skin of JunBDep mice.
Barrier defects are amajor hallmark of AD pathology and could
explain the dysbiosis in JunBDepmice (De Benedetto et al., 2011;
Weidinger et al., 2018). We therefore evaluated barrier function in
JunBDep mice. Lesional skin from JunBDep mice exhibited signif-
icant trans-epidermal water loss, similar to AD (Figure S1D).
Levels of loricrin, a component of the cornified cell envelope,
were also lost in lesional areas in JunBDepmouse skin, consistent
with compromised barrier function (Figure S1E). To investigate
whether this was due to the absence of JunB or secondary to
the skin inflammation, we examined JunBDep mouse skin prior
to the onset of skin inflammation, specifically during embryonic
development and neonatal life. We first evaluated JunBDep
mice pre-birth, at embryonic day 17.5, when the skin barrier is
already formed. Skin barrier function was evaluated using a
well-established protocol (Indra and Leid, 2011) in which em-
bryos were dipped into toluidine blue and assessed for skin
penetrance. By this assay, we observed marked toluidine blue
indicative of defective barrier function in JunBDep mice (Fig-
ure 1J). To assess barrier function post-birth, we measured
trans-epidermal water loss. Surprisingly, at 1 and 7 days post-
birth, the skin barrier appeared intact in the JunBDep mice,
suggesting compensatory mechanisms (Figure S1D). Further-
more, we used the biotin diffusion assay (Schmitz et al., 2015),
whereupon fluorescently labeled biotin was injected subcutane-
ously and the leakage of biotin past the tight junctions was
evaluated 1 day post-birth. We observed that the injected biotin
co-localized with occludin, staining the tight junctions, suggest-
ing intact inside-out barrier function (Figure S1F). Occludin
expression was more prominent in JunBDep mice compared
with controls, consistent with a compensatory strengthening of
tight junction formation. These data suggest that JunB is im-
portant for skin barrier function transiently before birth.
Overlapping Transcriptomic Signature with Human AD
and Both Type 2 and Type 17 Immune Activation Are
Observed in Lesional Skin of JunBDep Mice
Our results indicated that JunBDep mice exhibited clinical and
histopathological similarities with cutaneous dysbiosis and AD.
To determine whether the pathological features of JunBDep
skin were transcriptionally similar to AD, we carried out RNA
sequencing analysis from lesional skin of JunBDep mice at
6 months of age. Whole skin was isolated from three JunBDep
mice and three controls. Total skin was lysed and mRNA ex-
tracted and subjected to RNA sequencing. We identified 615differentially expressed genes (DEGs) with a false discovery
rate (FDR) value of <0.05 between JunBDep and controls. These
DEGs included genes involved in the immune/inflammatory
response, cytokine signaling, keratinization, and regulation of
defense responses, consistent with a chronic inflammatory
skin phenotype with bacterial colonization, similar to what is
observed in AD (Weidinger et al., 2018) (Figure 2A). Importantly,
several pathways dysregulated in AD were also upregulated in
our dataset, including IL-5, IL-23, IL-17, and Jak-Stat signaling
pathways (Figure 2B), noteworthy because many of these path-
ways are presently under clinical investigation for the treatment
of AD (Paller et al., 2017). We then carried out gene set enrich-
ment analysis, comparing the JunBDep skin transcriptome with
the MADAD (meta-analysis-derived AD) gene signature (Ewald
et al., 2015), a meta-analysis-derived DEG list from human AD
skin. We found a statistically significant positive correlation
between the JunBDep skin and the MADAD transcriptome (Fig-
ure 2C, left).
To further investigate the immune responses in thesemice, we
compared the transcriptomic signature of lesional JunBDep skin
with publicly available datasets investigating keratinocyte re-
sponses to two major pro-inflammatory cytokines present in
AD, IL-4, and IL-17A. Strikingly, we observed a statistically
significant positive correlation for both of these signatures to
JunBDep skin, indicating that both type 2 and type 17 immune re-
sponses are active in JunBDep skin (Figure 2C, middle and right).
A recent report comparing psoriasis and AD showed extensive
overlap of these two diseases at the transcriptomic level (Tsoi
et al., 2019). We evaluated whether expression of some of the
genes selectively regulated in AD, such as Duox1, Il13ra2,
Stac2, as well as other genes implicated in AD pathogenesis in
mice or humans such as Tslp, Aqp3, Il4ra, Nod2, Osm,
Slc4a11, Mmp13, and Serpinb3 were altered in JunBDep mice
(Olsson et al., 2006; Cianferoni and Spergel, 2014; Miyai et al.,
2016; Weidinger et al., 2018). We observed an upregulation of
a large proportion of these genes in JunBDep mice (Figure 2D).
Moreover, we observed a statistically significant correlation of
the transcriptome of JunBDep skin with that of ADAM17Dep
mice, recently published to model the AD transcriptome (Woodr-
ing et al., 2018) (Figure 2E).
Collectively, these data show that JunBDep mice have skin
inflammation with hallmarks of AD both at the phenotypic and
at the molecular level.
Skin Inflammation and S. aureus Colonization Are
Exacerbated in the Absence of Adaptive Immunity
We then conducted a detailed analysis of the immune cells in the
skin of JunBDep mice pre- and post-lesion development, which
demonstrated involvement of both the innate and adaptive im-
mune systems. Specifically, we observed increased monocytes,
neutrophils, TCRab T cells, and TCRgd T cells in JunBDep mice
(Figures 3A–3C). Interestingly, TCRab and TCRgd T cells were
increased prior to epidermal hyperplasia, whereas neutrophils
and monocytes were increased at later stages of disease (Fig-
ures 3A–3C). Furthermore, group 2 innate lymphoid cells
(ILC2s), which produce IL-13 and have been proposed to
contribute to the pathogenesis of AD (Kim et al., 2013; Roediger





Figure 2. Lesional Skin from JunBDep Mice Shows Overlapping Transcriptomic Signature with Human AD, with Both Type 2 and Type 17
Immune Activation
(A) Functional annotations derived from RNA sequencing (RNA-seq) analysis of skin from control (n = 3) and JunBDep mice (n = 3).
(B) Canonical pathways derived from RNA-seq analysis of skin from control (n = 3) and JunBDep mice (n = 3).
(C) Gene set enrichment analysis (GSEA) showing positive correlations with MADAD (meta-analysis-derived AD) signature, IL-4- and IL-17-responsive genes in
keratinocytes.
(D) Expression levels of genes implicated in AD pathology, as assessed by qPCR.
(E) Correlation of transcriptomic changes of commonly expressed genes in JunBDep mice versus Adam17Dep mice (Woodring et al., 2018).




Figure 3. T Cells and ILC2s Infiltrate Skin before the Onset of Overt Inflammation
(A and B) Representative flow cytometry plots showing (A) T cell subsets, ILCs, and (B) neutrophils, inflammatory monocytes of pre-lesional (3 months of age;
n = 3, 5) and lesional (6 months of age; n = 3, 5) skin in control and JunBDep mice.
(C) Absolute numbers of immune cell subsets as analyzed using flow cytometry of pre-lesional (3 months of age) and lesional (6 months of age) skin in control
and JunBDep mice. Markers defining each cell subset are as follows: abT cells: CD45+CD11b/ lowCD3+gdTCR; gdT cells: CD45+CD11b/lowCD3+gdTCRint;
DETC: CD45+CD11b/lowCD3higdTCRhi; CD2 ILCs: CD45+CD90hiCD11bCD3gdTCRCD2; Ly6G+ neutrophils: CD45+CD11bhiCD3gdTCRLy6Ghi;
Ly6Chi monocytes: CD45+CD11b+CD3gdTCRLy6GLy6ChiMHCII.
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epidermal hyperplasia, but their numbers normalized as inflam-
mation worsened (Figure 3C).
The role of T cells in cutaneous dysbiosis and AD pathogen-
esis remains incompletely understood. Generally, it is consid-
ered that type 2 inflammatory cytokine production by T cells
enables S. aureus colonization and that S. aureus-derived
superantigens activate T cells in the skin to promote inflamma-
tion (Bieber, 2008). In contrast, IL-17 production by T cells is
likely to serve anti-S. aureus function, partially via upregulation
of anti-microbial proteins (Cho et al., 2010). To investigate
whether T cells exacerbated or ameliorated inflammation
in JunBDep mice with spontaneous dysbiosis, we crossed
these mice to Rag1–/– mice, which lack mature T and B cells.
Strikingly, JunBDepRag1–/– mice developed exacerbated skin
inflammation at an earlier time point with higher S. aureus
load (Figure 4A). In 15% of JunBDepRag1–/– mice, S. aureus
caused superinfections and botryomycosis (data not shown).
We observed an increase in the number of mast cells by tolu-
idine blue staining and Langerhans cells by langerin staining in
JunBDepRag1–/– skin (Figure 4A). Importantly, we observed
equal or higher amounts of pro-inflammatory cytokines in the
3-month-old JunBDepRag1–/– (lesional skin) mice compared
with JunBDep mice (pre-lesional skin), including elevated
IL-4, IL-1b, and IL-22, as well as alarmins and the anti-micro-
bial proteins beta-defensin 14, Lipocalin-2 (Lcn-2), and
S100A9 (Figure 4B), confirming that the inflammatory media-
tors appear earlier in JunBDepRag1–/– compared with JunBDep
mice.
These data suggest that T cells are important for controlling
S. aureus in JunBDep mice, presumably via IL-17A production,
even though we cannot exclude the role of B cells,
also absent in Rag1/ mice. Consistent with this hypothesis,
JunBDep mice had higher serum IL-17A levels compared with
JunBDepRag1–/– mice (Figure 4C). IL-17A can be produced by
both TCRab T cells and TCRgd T cells, as well as ILC3s (Su-
maria et al., 2011; Spits et al., 2013; Ebbo et al., 2017). To
determine the cell type(s) responsible for IL-17A production
in JunBDep mice, we crossed these mice to an Il17a-eGFP re-
porter mouse (Lee et al., 2012). In these mice, cells expressing
Il17a express GFP, which is readily detectable using flow
cytometry. We observed basal Il17a-eGFP expression by
skin-resident TCRgd T cells but not TCRab T cells in control
mice and a massive upregulation of Il17a expression by
both TCRgd and TCRab T cells (Th17 cells) in JunBDep skin
(Figure 4D).
IL-17 can also be produced by ILC3s (Ebbo et al., 2017). Cyto-
kine production by ILC3s has been shown to be capable of
compensating for the absence of T cells to prevent colonic
infection with Citrobacter rodentium (Rankin et al., 2016). We
observed only modest Il17a expression in skin ILCs in (Rag-
sufficient) JunBDep skin (Figure 4E). However, wewere interested
in determining whether this changed in the absence of T cells.
We therefore examined IL-17A expression in JunBDepRag1–/–
mice on a Il17a-eGFP reporter background. In these mice, we
observed Il17a-eGFP expression only in ILCs, presumably
ILC3s. However, these Il17a+ ILC3s were substantially less
abundant than Il17a+ T cells in (Rag-sufficient) JunBDep skin
(Figure 4C). This was confirmed in unbiased t-Distributed850 Cell Reports 29, 844–859, October 22, 2019Stochastic Neighbor Embedding (t-SNE) analysis of the Il17a-
eGFP+ cells in JunBDep and JunBDepRag1–/– mice, which
indicated an increase in the number of GFP+ ILC3s in
JunBDepRag1–/– mice relative to JunBDep mice that was never-
theless substantially short of the T cell response observed in
Rag-sufficient mice (Figure 4E).
To determine whether ILC3s can compensate for T cells in a
setting where IL-17A is potently induced, we topically admin-
istered imiquimod (IMQ) to Rag-sufficient or Rag1–/– mice for
5 days. We observed Il17a-eGFP expression in Th17, TCRgd,
and ILCs upon IMQ administration to Rag-sufficient mice (Fig-
ures S3A and S3B). However, in Rag1–/– mice, the Il17a-eGFP
expression in ILC3s was not increased. Thus, this limited
capacity for Il17a+ ILC3s to compensate for T cells was
observed in both settings (i.e., JunBDepRag1–/– and following
topical treatment with IMQ, a potent stimulator of IL-17)
(Figure S3C).
In summary, in the absence of the adaptive immune system,
S. aureus colonization and skin inflammation were accelerated
and exacerbated, and this correlated with diminished IL-17A
production within the skin.
Prophylactic Antibiotics Reduce Skin Inflammation
before Microbial Dysbiosis
Antibiotics are often used in AD patients with limited efficacy,
hypothesized to be due to lack of specificity to S. aureus and
possibly lack of effect on S. aureus killing (Williams et al.,
2017). Indeed, understanding of the role of microbial dysbiosis
in AD is confounded by variable response to antibiotic treat-
ment. Thus, whether S. aureus colonization is causal or a
consequence of type 2 inflammation remains to be answered.
To investigate the pathological role of S. aureus colonization in
the skin inflammation observed in JunBDep mice, we treated
these mice with antibiotics pre- and post-S. aureus coloniza-
tion. We used the JunBDep mice crossed to Il17a-GFP reporter
mice to analyze IL-17A responses. Mice were put on antibi-
otics in their drinking water at weaning and observed until
their non-antibiotic-treated counterparts developed skin
inflammation (6–7 months). Importantly, at 1 month of age,
no colonization of S. aureus was observed, even though
some colonies of Gram-negative bacteria were observed in
JunBDep skin (data not shown). We observed a strong amelio-
ration of the skin inflammatory phenotype in JunBDep mice
treated with antibiotics, with reduced hyperkeratosis and
decreased immune cell infiltration (Figure 5A). Gram staining
identified decreased to non-detectable Gram-positive coloni-
zation on the skin of mice treated with antibiotics (Figure 5A).
Swabs taken from the skin of mice and grown on blood agar
plates showed reduced S. aureus burden in mice treated with
antibiotics (Figure 5B). Detailed flow cytometry analysis of the
skin of these mice demonstrated decreased IL-17A-producing
gdT cells as well as Th17 cells and ILCs (Figures 5C–5E). We
also observed a drop in the number of neutrophils and inflam-
matory macrophages in the skin of JunBDep mice treated with
antibiotics before the development of skin inflammation and
S. aureus colonization. These data suggest that S. aureus
colonization contributes to the development of chronic skin





Figure 4. Skin Inflammation and S. aureus Colonization Are Exacerbated in the Absence of Adaptive Immunity
(A) Representative images of Gram, langerin, and toluidine blue of skin in JunBDep and JunBDepRag1–/– mice at 3 months of age (n = 6, 6). The yellow scale bar
indicates 200 mm.
(B)Relative expression levels of pro-inflammatory cytokines in the skin of JunBDepand JunBDepRag1–/–mice at 3months of agecomparedwith controls (n =3, 5, 6).
(C) Serum IL-17A levels in JunBDep and JunBDepRag1–/– mice at 3 months of age compared with controls (n = 7, 11, 9).
(D) Representative flow cytometry plots with GFP+ cells overlaid in the skin of JunBDep and JunBDepRag1–/– mice at 4 months of age compared with controls. The
cells shown are gated on CD45+CD90+CD11b.
(E) Heatmaps showing IL-17A expression on t-SNE plots from total IL-17A-eGFP+ cells. Themap on the right is created using conventional gating, as described in
Figure 2.
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Antibiotic Treatment Post-development of Skin
Inflammation Does Not Provide Therapeutic Benefit
Because we observed decreased skin inflammation when mice
were treatedwith antibiotics before skin inflammation and dysbio-
sis occurred, we then moved to a therapeutic model. JunBDep
Il17a-GFP reporter mice were put on antibiotics in their drinking
water after the development of skin inflammation at 6 months for
either 1 or 2 weeks, prior to immunological assessment as above.
t-SNE analysis, as well as conventional flow cytometry anal-
ysis, of the lymphoid and the myeloid cells in the skin of mice
upon either 1 or 2 weeks of antibiotic treatment illustrated a tran-
sient decrease in the total number of ab and gdT cells, with no
major changes in neutrophil and monocyte numbers (Figure 6A;
Figures S4 and S5). With regard to the IL-17A-producing cells, at
1 week, the effect of antibiotics was minimal, with a slight trend
towards reduced numbers of Il17a-GFP+ gdT cells and ILC3s in
skin of mice treated with antibiotics (Figures 6A and 6B). At
2 weeks post-antibiotics, we observed a statistically significant
decrease in the number of Il17a-GFP+ gdT cells (Figures 6A
and 6B; Figure S4). Unexpectedly, the number of skin neutro-
phils was increased 1 week post-antibiotics, but this trend did
not continue 2 weeks post-antibiotics (Figure 6B; Figure S4).
abT cell numbers were increased in the skin-draining lymph
nodes of these mice, whereas no changes were observed in
the number Il17a-GFP+ gdT cells, Th17 cells, neutrophils, or
monocytes (Figure S6). Swabs from mice grown on blood agar
plates showed a general reduction of S. aureus colonies upon
antibiotic treatment, although the extent of reduction was vari-
able (Figure 6C). To determine whether antibiotic resistance
might account for the variability observed in the different mice,
we subjected another set of JunBDep mice at 6 months of age
to antibiotics for 3 weeks, following the bacterial burden over
time. Interestingly, not all mice behaved the same upon antibiotic
treatment. Although some mice were sensitive to antibiotics,
others were completely resistant (Figure S7A). Flow cytometric
analysis at the 3 week time point showed that mice that were
sensitive to antibiotics had smaller numbers of gdT cells, abT
cells, ILCs, neutrophils, and inflammatory monocytes in the
skin compared with resistant mice (Figure S7B). Of note, these
short antibiotic treatment schemes did not lead to any discern-
able macroscopic changes in the clinical features of these
mice (data not shown). These data suggest that IL-17A-produc-
ing cells are linked to the bacterial burden, and antibiotic treat-
ment post-dysbiosis leads to a transient induction in macro-
phage and neutrophil numbers. However, resistance occurs in
a subset of mice upon continued antibiotic administration. Addi-
tional studies will be needed to delineate the differences in the
microbiota composition of themice showing antibiotic sensitivity
versus resistance.Figure 5. Prophylactic Antibiotics Reduce Skin Inflammation
(A) Representative H&E and Gram staining images of control and JunBDep mice w
bar indicates 200 mm.
(B) Blood agar plates from swabs from control and JunBDep skin with or without pr
(C) Number of infiltrating immune cells into the skin of control and JunBDepmice w
strategy as described in Figure 2.
(D) Representative flow cytometry images of IL-17A expressing T cells of contro
(E) Representative flow cytometry images of IL-17A expressing ILCs of control aMyD88 Signaling Is Upregulated in JunBDep Skin,
and MyD88 Is Upregulated in JunB-Deficient
Keratinocytes
IL-36a has recently been implicated to be upregulated by
S. aureus and orchestrate the downstream IL-17 signaling
events (Liu et al., 2017; Nakagawa et al., 2017). Consistent
with this, we observed elevated Il36a and Il36b and Il36g
expression levels in lesional skin of JunBDep mice (Figure 7A).
To determine whether the trigger for the elevated Il36a levels
was due to microbial signals or deletion of JunB, we turned
to in vitro keratinocyte cultures. Specifically, keratinocytes
isolated from JunBlox/lox mice were subjected to infection by
adenoviruses expressing Cre recombinase and empty adenovi-
ruses as control. JunB-deficient and JunB-sufficient keratino-
cytes were then exposed to microbial antigens produced
from supernatants derived from swabs applied onto JunBDep
lesional skin (Figure 7B). Deletion of JunB in keratinocytes
in vitro led to higher Il36a relative to controls, which was not
further enhanced by microbial signals (Figure 7C). Expression
of genes encoding several alarmins, such as the S100A9 and
Lcn-2, as well as inflammation-associated chemokines Cxcl1,
Cxcl2, and Ccl2 were upregulated in keratinocytes upon incu-
bation with the microbial supernatant, and these responses
were further upregulated in keratinocytes lacking JunB
(Figure 7C).
As MyD88 is downstream of IL-36 signaling, we checked
whether MyD88-mediated signaling is upregulated in JunBDep
lesional skin. MyD88 was predicted as one of the upstream reg-
ulators of the global changes in gene expression by Ingenuity
Pathway Analysis (IPA), and many genes downstream of
MyD88 were significantly regulated (Figure 7D). Moreover, an in-
crease in MyD88 protein levels was observed in keratinocytes
lacking JunB, which was not further increased upon microbial
signals (Figure 7E). In vivo, we observed increased levels of
MyD88 protein in keratinocytes and immune cells in JunBDep
skin, as assessed by immunohistochemistry (Figure 7F). These
data suggest that JunB negatively regulates IL-36 and MyD88
levels in keratinocytes, which have been shown to be important
for the colonization of S. aureus on skin (Figure 7G).
DISCUSSION
In this study, we show that epithelial expression of JunB is a
gatekeeper of immune-microbiota interactions, and its loss
leads to chronic skin inflammation with spontaneous S. aureus
colonization. JunBDep mice share many pathological aspects of
AD, including but not limited to type 2 and type 17 immune re-
sponses, elevated IgE levels, barrier dysfunction, and, impor-
tantly, spontaneous S. aureus colonization.ith or without prophylactic antibiotics (UT: n = 4, 3; Ab: n = 2, 5). The blue scale
ophylactic antibiotic treatment and quantification of total bacterial load on skin.
ith or without prophylactic antibiotics as analyzed using flow cytometry. Gating
l and JunBDep mice with or without prophylactic antibiotics.
nd JunBDep mice with or without prophylactic antibiotics.




(legend on next page)
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We took advantage of this mouse model to address some
unanswered questions, such as the role of T cells in controlling
S. aureus and the role of IL-17A in ADwithS. aureus colonization.
IL-17, a potent pro-inflammatory cytokine, is central to the
pathogenesis of psoriasis, and IL-17 blockers have shown un-
precedented success in the treatment of this disease (Lebwohl
et al., 2011; Langley et al., 2014; Ratner, 2015). IL-17 is produced
by T helper cell subset Th17, aswell as gdT cells and ILC3s. IL-17
is upregulated in AD skin, albeit at lower levels compared with
psoriasis, but its role in AD remains unclear (Guttman-Yassky
et al., 2008). Whether IL-17A has a protective or pathogenic
role in pediatric or adult AD remains to be understood. Eluci-
dating the role of IL-17A in AD is important, as blockade of
IL-17A and its upstream cytokine IL-23 is currently being tested
in clinical trials for AD (Paller et al., 2017).
ILCs have been proposed to play a protective role in
S. aureus- and pneumonia-induced inflammatory processes
(Rak et al., 2016; Gray et al., 2017), and ILC2s have been
shown to accumulate in the skin of AD patients (Kim et al.,
2013; Salimi et al., 2013). Kinetic analysis of the ILCs in the
skin of JunBDep mice showed a transient increase in the num-
ber of ILCs before the appearance of overt skin inflammation
and S. aureus colonization. However, there were no differences
in the number of ILCs infiltrating the lesional skin, whereas an
increased number of IL-17A+ ILCs (ILC3s) were observed. In
the presence of T cells, we observed a minor contribution of
ILC3s to the IL-17A-producing population. However, in
Rag1–/– mice, the number of IL-17A expressing ILC3s
increased, albeit not to sufficient levels to compensate for the
T cell deficit. These data suggest that ILC3s are only partially
redundant with T cells in the skin. Future studies are needed
to determine whether ILC3s are present in AD skin and the level
of plasticity observed between group 2 and group 3 ILCs in AD.
Barrier defects, caused for example by filaggrin mutations,
have been linked to the pathogenesis of AD. However, it is
important to note that about 40% of individuals with filaggrin
mutations never show AD symptoms (ORegan et al., 2009).
Thus, it is likely that barrier defects are not sufficient to lead
to the development of AD, and a second hit, possibly from
the environment, is needed to induce the inflammatory re-
sponses in skin. Along with these findings in humans, the filag-
grin-deficient mice, which have a clear skin barrier defect, do
not develop inflammation until 20–28 weeks of age (Oyoshi
et al., 2009). Moreover, filaggrin defects are shown not to be
sufficient to induce spontaneous AD-like lesions in many re-
ports. Most studies add an allergen such as house dust mite
to induce inflammation in mice with filaggrin defects (Moniaga
and Kabashima, 2011; Kawasaki et al., 2012). We hypothesize
that in the JunBDep mice, the early-life barrier dysfunction ren-Figure 6. Antibiotic Treatment Post-development of Skin Inflammation
(A) t-SNE plots showing the distribution of lymphoid (top) and myeloid (bottom) ce
controls as analyzed using flow cytometry. Maps on the left were made using co
JunBDep UT, n = 5; 1 week, n = 4; 2 weeks, n = 5).
(B) Number of infiltrating immune cells into the skin of JunBDep mice with or with
ventional flow cytometry.
(C) Blood agar plates from swabs from JunBDep mice with or without 1 and 2 wee
quantification of total bacterial load on lesional skin.ders the skin more sensitive to allergens and microbes, in this
case, particularly S. aureus.
The dysbiosis observed in JunBDep mice likely precedes
inflammation, as prophylactic antibiotic treatment restricted
the development of skin inflammation and strongly ameliorated
epidermal hyperproliferation. In contrast, antibiotic treatment af-
ter S. aureus colonization demonstrated variable efficacy in
JunBDepmice. Thismirrors the clinical reality of AD, in which anti-
biotic treatment often demonstrates little to no success in con-
trolling disease. The reason for the disparate efficacy of prophy-
lactic versus therapeutic antibiotic treatment remains unknown.
This may reflect antibiotic access or efficacy within inflamed skin
and/or active drug resistance mechanisms in established
S. aureus. Alternatively, there may be other species of anti-
biotic-susceptible bacteria that are necessary for S. aureus colo-
nization but dispensable once colonization has established. In
JunBDep mice, we detected small amounts of Gram-negative
bacteria at early time points, before the colonization of
S. aureus, that did not correlate with disease. Thus, although
we cannot formally exclude that other bacteria might initiate dys-
biosis in these mice, because of their low abundance and vari-
ability, they are unlikely to be directly responsible for the
observed pathology. With growing advances in microbiome
sequencing technology, these questions will be addressable in
the near future.
The mechanisms by which S. aureus is sensed by different cell
types in the skin and the downstream signaling pathways acti-
vated have recently gained a lot of attention (Bitschar et al.,
2017). Pattern recognition receptors such as Toll-like receptors
(TLRs), aswell as NOD receptors, have been shown to contribute
to the initial recognition of bacterial antigens. Activation of the
TLRs leads to NF-kB activation via MyD88 signaling (Kawai
and Akira, 2010). Mutations in TLR2 decreasing intracellular
signaling have been linked to higher S. aureus load and disease
severity in AD (Bin and Leung, 2016). However, the mechanisms
leading to susceptibility to develop AD are still not well under-
stood. An important finding of our study is the observation that
JunB loss in keratinocytes is sufficient to drive skin inflammation,
likely through a combination of dysbiosis due to barrier dysfunc-
tion and the enhanced responses to dysbiosis. Mechanistically,
JunB negatively regulates MyD88, because its deletion in kerati-
nocytes in vitro is sufficient for upregulation of many chemokines
and alarmins, including IL-36a, previously reported to be
secreted from keratinocytes upon S. aureus colonization (Liu
et al., 2017). The transcriptomic profile of the JunBDep skin
shows regulation of several pathways such as TLR signaling,
as well as many anti-microbial molecules, such as Lcn-2. Inter-
estingly, deletion of p65 in keratinocytes in JunBDep mice led
to exacerbated skin inflammation with higher S. aureus load,Does Not Provide Therapeutic Benefit
lls in JunBDep mice with or without 1 and 2 weeks of antibiotics compared with
nventional gating as described in Figure 2. UG, ungated (control [Ctrl], n = 6;
out 1 and 2 weeks of antibiotics compared with controls as analyzed by con-
ks of antibiotics compared with controls as analyzed using flow cytometry and






Figure 7. MyD88 Signaling Is Upregulated in JunBDep Skin, and MyD88 Is Upregulated in JunB-Deficient Keratinocytes
(A) Relative expression levels of il1f6 (Il36a), Il1f8 (Il36b), and Il1f9 (Il36g) in the lesional skin of JunBDep mice compared with controls (n = 5, 6).
(B) Schematic diagram depicting the experimental design for (C) and (E).
(C) Relative expression levels of chemokines and alarmins upon JunB deletion in JunBlox/lox keratinocytes using adenoviruses expressing Cre recombinase with
or without supernatant (S/N) derived from swabs from lesional skin of JunBDep mice (n = 3, 3, repeated three separate times).
(D) MyD88 and its downstream genes are significantly regulated in the transcriptome of JunBDep skin.
(E) Western blot using control or JunBDep keratinocytes upon S/N administration (as described in B) for indicated time points. MyD88 levels and vinculin (as
loading control) are shown.
(legend continued on next page)
856 Cell Reports 29, 844–859, October 22, 2019
highlighting that the NF-kB pathway in keratinocytes is protec-
tive for skin homeostasis in the presence of S. aureus (data not
shown). These data suggest that loss of JunB in keratinocytes
is a susceptibility factor for the development of S. aureus-
induced skin inflammation. Unfortunately, there are no protein
data available from patients with overt S. aureus colonization
and superinfections compared with non-overt/limited S. aureus
colonization to determine the co-localization of bacterial col-
onies and keratinocyte JunB expression. A prospective study
making use of biopsies without prior desterilization conditions
will be necessary to answer this question.
In summary, we show that JunB is a critical transcription factor
in immune-microbiota crosstalk and that its loss is detrimental
for skin immunity. These findings highlight the essential role of
keratinocytes, an underestimated cell type in skin inflammation.
We also show that JunB negatively regulates MyD88 in keratino-
cytes. These mice are an ideal model to further investigate the
role of the microbiota and S. aureus in AD, as they represent
the natural evolution of skin inflammation resembling AD.
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Uluçkan, Ö., Jimenez, M., Karbach, S., Jeschke, A., Graña, O., Keller, J.,
Busse, B., Croxford, A.L., Finzel, S., Koenders, M., et al. (2016). Chronic skin
inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling
in osteoblasts. Sci. Transl. Med. 8, 330ra37.
Weidinger, S., Beck, L.A., Bieber, T., Kabashima, K., and Irvine, A.D. (2018).
Atopic dermatitis. Nat. Rev. Dis. Primers 4, 1.
Welch, J.S., Escoubet-Lozach, L., Sykes, D.B., Liddiard, K., Greaves, D.R.,
and Glass, C.K. (2002). TH2 cytokines and allergic challenge induce Ym1
expression in macrophages by a STAT6-dependent mechanism. J. Biol.
Chem. 277, 42821–42829.
Werfel, T., Allam, J.P., Biedermann, T., Eyerich, K., Gilles, S., Guttman-Yassky,
E., Hoetzenecker, W., Knol, E., Simon, H.U., Wollenberg, A., et al. (2016).
Cellular and molecular immunologic mechanisms in patients with atopic
dermatitis. J. Allergy Clin. Immunol. 138, 336–349.
Williams, M.R., Nakatsuji, T., and Gallo, R.L. (2017). Staphylococcus aureus:
Master Manipulator of the Skin. Cell Host Microbe 22, 579–581.
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Junbtm3Wag/J crossed to K5-Cre
N/A N/A
Mouse: Rag1/: B6.129S7-Rag1tm1Mom/J N/A N/A
Mouse: IL-17A-eGFP: C57BL/6-Il17atm1Bcgen/J N/A N/A
Oligonucleotides
Oligos for q-RT-PCR See Table S1 for oligo sequences N/A
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Nextpresso Graña et al., 2018 http://bioinfo.cnio.es/nextpresso/
FastQC (v 0.11.0) https://www.bioinformatics.babraham.
ac.uk/projects/fastqc/
Bowtie (v 1.0.0 70) Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/
bowtie2/index.shtml
SAMtools (v 0.1.19 71) Li et al., 2009 http://samtools.sourceforge.net/
GSEA v(2.08) Subramanian et al., 2005 http://software.broadinstitute.org/gsea/index.jsp
TopHat (v 2.0.10 69) Kim et al., 2013 https://ccb.jhu.edu/software/tophat/index.shtmlLEAD CONTACT AND MATERIALS AVAILABILITY
Further information may be directed to and will be fulfilled by the Lead Contact, Özge Uluçkan (ozge.uluckan@novartis.com). This
study did not generate new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All mouse experiments were performed in accordance with local and institutional regulations/licenses. The generation of the JunBDep
mice has previously been described (Meixner et al., 2008). JunBDepmicewere backcrossed toC57B/6 for at least 7 generations.Micee1 Cell Reports 29, 844–859.e1–e3, October 22, 2019
of both sexes were included in the study, since no gender differences were observed. Il17a-eGFP (C57BL/6-Il17atm1Bcgen/J) mice,
originally generated at Biocytogen and previously described (Lee et al., 2012), were purchased from Jackson Laboratory.
METHOD DETAILS
Histological analyses
Tissues were fixed in phosphate-buffered saline–buffered 3.7% formalin. H&E staining was performed according to standard
procedures (Sigma). Immunohistochemistry was performed with Elite ABC Kit (Vectastain) and DAB (Vector Laboratories). Immuno-
fluorescence was performed as described previously (Guinea-Viniegra et al., 2014). In short, tissues were fixed in phosphate-
buffered saline–buffered 3.7% formalin. Primary antibodies were incubated overnight at 4C and secondary antibodies for 1 hour
at RT. Counterstainings were performed with 40,6-diamidino-2-phenylindole (Sigma) and sections were mounted using Prolong
Gold anti-fade reagent (ThermoFisher).
Gram staining was carried out using provider’s instructions (Sigma). Toluidine Blue staining was performed using standard proto-
cols. S. aureus antibody was purchased from Abcam (ab20920), Loricrin and Keratin 6 antibodies from Covance (PRB-145P), and
MyD88 antibody (D80F5) from Cell Signaling. Secondary antibodies were purchased from Invitrogen and used at 1:250 dilution.
Barrier analysis
Trans-epidermal water loss was measured using Tewameter TM300 from Courage-Khazaka.
Outside-in Toludine blue assaywas carried out as described in Indra and Leid (2011) and briefly embryos isolated at embryonic day
E17.5 were incubated in methanol for 5 mins, rinsed in PBS, then incubated in 0.1% Toluidine Blue for 5 mins. Embryos were kept in
PBS and photographed immediately afterward.
Inside-out biotin diffusion assay was carried out as described in Schmitz et al. (2015). 10 mg/ml EZ-Link sulfo-NHS-LC-biotin
(Pierce Chemical Co., Rockford, IL) in PBS containing 1 mM CaCl2 was injected intradermally into the back skin of 1-day old
mice. After 30 minutes, mice were sacrificed and the skin was embedded in Tissue-Tek and snap-frozen on dry ice. Paraformalde-
hyde-fixed cryosections were stained with Occludin antibody (Thermo-Fisher-Zymed (40-6100)). Sections were then stained with
streptavidin-AF488 (Invitrogen), a AF555-labeled secondary antibody to detect occludin and DAPI to visualize the nuclei.
Flow cytometry
Skin frommice was isolated and subjected tomild digestion with liberase (RocheTM), andmechanically disrupted using GentleMACS
Dissociator (Miltenyi). The single cell suspension was stained with either CD45-APCCy7 (Biolegend), CD3-PE (Biolegend), gdTCR-
Brilliant Violet 421 (Biolegend), CD90.2-APC (BD PharMingen), Cd11b-PerCPCy5.5 (BD PharMingen) and CD2-PECy7 (Biolegend),
or CD45-APCCy7 (Biolegend), MHCII-PacBlue (Biolegend), Ly6C-APC (BD PharMingen), Ly6G-PE (BD PharMingen), CD11b-PECy7
(BD PharMingen). Samples were collected in a FACS CANTO II (BD, San Jose CA) equipped with 488nm, 640nm and 405nm lines.
We used pulse processing to exclude cell aggregates and live/dead fixable dye Aqua (Invitrogen) to exclude dead cells. At least
100,000 alive single events were collected; all data were analyzed using FlowJo v10 (Treestar, Oregon).
Antibiotic administration
Enrofloxacin (Baytril) (0.025%) was added to the drinking water either at weaning (for prophylactic experiments) or at 6 months of
age for 1, 2 or 3 weeks and changed every 3 days. For the prophylactic experiments, enrofloxacin was kept in the drinking water
thoughout the lifetime of the mice.
Bacterial analysis
Columbia agar +5%Sheep blood plates andMannitol-salt agar plates were purchased fromBiomerieux (43041, 43671). Swabswere
dipped in PBS, lesional skin of mice were swabbed and the swabs were directly inoculated on the plates. Plates were incubated at
37C for 24 hours. DNA was isolated from single colonies grown on blood agar plates, and PCR was carried. Oligo sequences are
included in Table S1. USA300 S. aureus strain and a specimen from a nearby hospital were used as positive controls. To measure
CFUs of S. aureus, we performed a standard plate count method. Briefly, skin swabs from the lesional skin of JunBDep mice (1 cm2),
and equivalent area in control mice were placed into 1 mL of PBS, and serial dilutions were prepared. 200 mL of each dilution was
transferred on blood agar plates, and colonies were counted after a 1-day incubation. CFUs were calculated by dividing the number
of colonies per plate by the dilution factor.
Transcriptomic analysis
Samples of 1ug of total RNA were used. Average sample RNA integrity number was 7.75 (range 7-9.2) when assayed on Agilent
2100 Bioanalyzer. PolyA+ fraction was purified and randomly fragmented, converted to double stranded cDNA and processed
through subsequent enzymatic treatments of end-repair, dA-tailing, and ligation to adapters as in Illumina’s ‘‘TruSeq Stranded
mRNA Sample Preparation Part # 15031047 Rev. D’’ kit (this kit incorporates dUTP during 2nd strand cDNA synthesis, which
implies that only the cDNA strand generated during 1st strand syntesis is eventually sequenced). Adaptor-ligated library was
completed by PCR with Illumina PE primers. The resulting purified cDNA library was applied to an Illumina flow cell for clusterCell Reports 29, 844–859.e1–e3, October 22, 2019 e2
generation and sequenced on an Illumina instrument (see below) by following manufacturer’s protocol. Sequencing reads were
analyzed with the nextpresso pipeline (Graña et al., 2018), as follows: sequencing quality was checked with FastQC v0.11.0
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were aligned to the mouse genome (NCBI37/mm9) with
TopHat-2.0.10 (Trapnell et al., 2013) using Bowtie 1.0.0 (Langmead et al., 2009) and SAMtools 0.1.19 (Li et al., 2009), allowing 2
mismatches and 20 multihits. Differential expression was tested with DESeq2 (Love et al., 2014), using the mouse NCBI37/mm9
transcript annotations from https://ccb.jhu.edu/software/tophat/igenomes.shtml. GSEAPreranked (Subramanian et al., 2005) was
used to perform gene set enrichment analysis of the described gene signatures on a pre-ranked gene list, setting 1000 gene set
permutations.
QUANTIFICATION AND STATISTICAL ANALYSIS
Two-tailed students’s t test after Shapiro-Wilk normality test was used to determine statistical significance. Linear regression
analyses was used for the correlation study in Figure 2E. One-way ANOVA with multiple-comparisons was used for Figures 4C
and 6B and 7C.
DATA AND CODE AVAILABILITY
Data from RNA sequencing analysis has been deposited to GEO with accession number GEO: GSE136657.e3 Cell Reports 29, 844–859.e1–e3, October 22, 2019
